Valuation: Vectus Biosystems Limited

Market Cap 7.69M 5.5M 4.71M 4.42M 4.03M 7.61M 524M 52.08M 20.28M 265M 20.65M 20.2M 876M P/E 2024
-1.75x
P/E 2025 -1.2x
Enterprise Value 7.64M 5.46M 4.68M 4.39M 4.01M 7.56M 521M 51.74M 20.14M 263M 20.51M 20.06M 870M EV / Sales 2024
2.91x
EV / Sales 2025 4.35x
Free-Float
57.14%
Yield 2024 *
-
Yield 2025 -
1 week-11.76%
Current month+15.38%
3 months+30.43%
6 months+7.14%
Current year-16.67%
1 week 0.15
Extreme 0.15
0.17
1 month 0.13
Extreme 0.13
0.17
Current year 0.09
Extreme 0.09
0.22
1 year 0.05
Extreme 0.053
0.46
3 years 0.04
Extreme 0.037
0.46
5 years 0.04
Extreme 0.037
2.2
10 years 0.04
Extreme 0.037
2.2
Manager TitleAgeSince
Chief Executive Officer - 07/05/2026
Corporate Secretary - 09/07/2015
Director TitleAgeSince
Director/Board Member - 12/12/2005
Chairman - 31/08/2018
Director/Board Member - 20/12/2024
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-11.76%+87.50%-62.50% 6.6M
+1.02%+4.95%+3.67%+25.46% 51.21B
-0.51%-2.19%+492.28%+537.49% 45.35B
-0.48%+8.10%+38.01%+18.48% 42.84B
+1.35%+2.50%+22.60%+90.71% 42.29B
-2.27%-5.67%+14.55%+50.34% 32.15B
-1.21%+3.56%+30.96%+135.29% 17.31B
+0.25%+1.29% - - 16.55B
+1.12%+6.35%+11.00%+32.62% 14.84B
+0.41%+7.46%+82.81%+49.71% 14.25B
Average -0.02%+1.57%+87.04%+97.51% 27.68B
Weighted average by Cap. +0.01%+2.89%+105.45%+136.25%

Financials

2024 2025
Net sales 1.14M 815K 698K 654K 597K 1.13M 77.66M 7.72M 3M 39.18M 3.06M 2.99M 130M 478K 342K 293K 275K 251K 474K 32.61M 3.24M 1.26M 16.45M 1.28M 1.26M 54.49M
Net income -2.34M -1.67M -1.43M -1.34M -1.23M -2.32M -159M -15.84M -6.17M -80.46M -6.28M -6.14M -266M -1.78M -1.27M -1.09M -1.02M -933K -1.76M -121M -12.04M -4.69M -61.16M -4.77M -4.67M -203M
Net Debt -780K -558K -478K -448K -409K -772K -53.2M -5.29M -2.06M -26.84M -2.1M -2.05M -88.89M -50.99K -36.48K -31.26K -29.29K -26.75K -50.49K -3.48M -345K -134K -1.75M -137K -134K -5.81M
Logo Vectus Biosystems Limited
Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.
Employees
-
Date Price Change Volume
25/08/26 A$0.1500 0.00% 4,859
24/08/26 A$0.1500 -6.25% 3,050
21/08/26 A$0.1600 -5.88% 61
20/08/26 A$0.1700 0.00% 35
19/08/26 A$0.1700 0.00% 11,764